Table 1 Summarized characteristics of IRE cohort patients (N = 60)
From: MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study
Characteristics | N(%) |
|---|---|
Age yr, median (range) | 55 (36–81) |
BRCA 1/2 status | |
 Wild Type | 54 (90%) |
 Mutated | 6 (10%) |
Hystology | |
 Serous carcinoma | 45 (75.0%) |
 Clear cell carcinoma | 4 (6.7%) |
 Mixed serous and clear cell carcinoma | 1 (1.6%) |
 Poorly differentiated carcinoma | 6 (10.0%) |
 Not otherwise specified carcinoma | 4 (6.7%) |
Disease setting (FIGO Stage) | |
 Metastatic (Stage IV) | 11 (18.3%) |
 Adjuvant (Stage I - IIIB) | 27 (45.0%) |
 Neoadjuvant (IIIC) | 22 (36.7%) |
First systemic treatment | |
 Carboplatin + Paclitaxel | 54 (90%) |
 Carboplatin + Paclitaxel + Bevacizumab | 4 (6.8%) |
 Carboplatin + Docetaxel | 1 (1.6%) |
 Cisplatin + Gemcitabine | 1 (1.6%) |